Thus, crystal-induced TNF-α release and the subsequent TNFR1-triggered activation of RIPK1–RIPK3–MLKL-executed tubular cell necroptosis represent therapeutic targets in CN. This evidence concerns the gene RIPK3 and cyclic hematopoiesis.